Trials / Completed
CompletedNCT06045000
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants
A Phase 1 Study to Assess the Excretion Balance, Pharmacokinetics, and Metabolism of [14C]-DC-806 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to investigate the rate and routes of excretion, including the mass balance, after single oral dose administration of DC-806 containing 3.7 MBq (100 μCi) of \[14C\]-DC-806 in urine and feces.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DC-806 | Oral tablets |
| DRUG | [14C]-DC-806 | Oral capsules |
Timeline
- Start date
- 2023-09-14
- Primary completion
- 2023-10-02
- Completion
- 2023-10-02
- First posted
- 2023-09-21
- Last updated
- 2025-05-04
Locations
1 site across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06045000. Inclusion in this directory is not an endorsement.